Thymosin Alpha-1: An Approved Immune Drug in Much of the World

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymus tissue, and it is an approved medicine in dozens of countries. It is not approved in the United States, which is the split that makes it unusual in this category.

That combination — real approvals abroad, none domestically — means it has a genuine clinical evidence base while still being sold as a research chemical in the US market.

What it does

Thymosin alpha-1 is an immunomodulator rather than an immune stimulant, a distinction worth holding onto. It affects T-cell maturation and function and influences the balance of immune signalling rather than simply turning activity up.

The thymus produces it naturally, and thymic function declines substantially with age — which is the observation behind much of the interest, in the same way declining levels drive interest in NAD+ and GHK-Cu.

Not the same as thymosin beta-4

This is the most common confusion, and the names invite it. Thymosin alpha-1 and thymosin beta-4 are different peptides with different sequences and unrelated proposed functions.

The BPC-157 and TB-500 guide covers the beta-4 fragment. The two share a name prefix and nothing else of consequence.

Where the clinical evidence sits

• Hepatitis B and C, the indications underpinning many of its approvals.

• Immune support in oncology, as an adjunct, which is where much of the current literature is focused.

• Sepsis and severe infection, studied with mixed results.

• Vaccine response, in populations with impaired immune function.

The vial math

Supplied lyophilised, commonly in 5 mg or 10 mg vials, with figures discussed in the low milligram range.

The peptide calculator converts any vial and target into units.

Storage

Storage is the same as any reconstituted vial: 2–8 °C, protected from light, never frozen, and bounded by the shorter of peptide stability and the 28-day limit on bacteriostatic water. The bacteriostatic water guide covers the detail.

Frequently asked questions

Is thymosin alpha-1 approved in the US?

No. It has approvals in many other countries, which is a different thing and does not make US-sold research material a regulated pharmaceutical.

Is it the same as TB-500?

No. Different peptide, different sequence, different proposed function. Only the "thymosin" prefix is shared.

Does it boost the immune system?

It is described as a modulator rather than a stimulant, and the clinical research is largely in people with impaired immune function rather than healthy ones.